BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. BMC Infect Dis 2018;18:223. [PMID: 29769038 DOI: 10.1186/s12879-018-3125-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Politi J, Guerras JM, Donat M, Belza MJ, Ronda E, Barrio G, Regidor E. Favorable impact in hepatitis C-related mortality following free access to direct-acting antivirals in Spain. Hepatology 2022;75:1247-56. [PMID: 34773281 DOI: 10.1002/hep.32237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
3 Rial-Crestelo D, Sepúlveda MA, González-Gasca FJ, Geijo-Martínez P, Martínez-Alfaro E, Barberá JR, Yzusqui M, Casallo S, García M, Muñoz Hornero C, Espinosa-Gimeno A, Torralba M; Grupo de Estudio de Castilla la Manche de enfermedades Infecciosas (GECMEI). Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018). Eur J Gastroenterol Hepatol 2021;32:279-87. [PMID: 33252415 DOI: 10.1097/MEG.0000000000002012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li J, Gordon SC, Zhou Y, Boscarino JA, Schmidt MA, Daida YG, Rupp LB, Trudeau S, Lu M; CHeCS Investigators. Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C. Am J Gastroenterol 2021;116:576-83. [PMID: 33399360 DOI: 10.14309/ajg.0000000000001095] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Namayandeh M, Jamalidoust M, Heydari Marandi N, Aliabadi N, Ziyaeyan A, Pouladfar G, Ziyaeyan M. Hepatitis C virus genotypes in patients with chronic hepatitis C infection in southern Iran from 2016 to 2019. Microbiol Immunol 2020;64:762-7. [PMID: 32902892 DOI: 10.1111/1348-0421.12845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Ireland G, Simmons R, Hickman M, Ramsay M, Sabin C, Mandal S. Monitoring liver transplant rates in persons diagnosed with hepatitis C: a data linkage study, England 2008 to 2017. Euro Surveill 2019;24. [PMID: 31615597 DOI: 10.2807/1560-7917.ES.2019.24.41.1900176] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Castellote J, Gea F, Morano LE, Morillas RM, Pineda JA, Vergara M, Buti M. Factors influencing hepatitis C cure in the era of direct-acting antivirals. Gastroenterol Hepatol 2019;42 Suppl 1:1-7. [PMID: 32560767 DOI: 10.1016/S0210-5705(20)30181-3] [Reference Citation Analysis]
8 Monte-Boquet E, Verdugo RM, Navarro H, Quer JC, Ventayol P. Importance of adherence to treatment with direct-acting antivirals in hepatitis C. Gastroenterol Hepatol 2019;42 Suppl 1:14-9. [PMID: 32560768 DOI: 10.1016/S0210-5705(20)30183-7] [Reference Citation Analysis]
9 Michels FBL, Amaral ACC, Carvalho-Filho RJ, Vieira GA, Souza ALDS, Ferraz MLG. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Arq Gastroenterol 2020;57:45-9. [PMID: 32294735 DOI: 10.1590/S0004-2803.202000000-09] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Cabalak M, Bal T, Onlen Y, Demir M. Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection. Trop Doct 2020;50:141-6. [PMID: 31810415 DOI: 10.1177/0049475519892082] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Lobato CMO, Codes L, Silva GF, Souza AFM, Coelho HSM, Pedroso MLA, Parise ER, Lima LMSTB, Borba LA, Evangelista AS, Rezende REF, Cheinquer H, Kuniyoshi ASO, Aires RS, Quintela EHD, Mendes LSC, Nascimento FCV, Medeiros Filho JEM, Ferraz MLCG, Abdala E, Bittencourt PL; Members of the Brazilian Real-Life Study about HCV treatment., Members of the Brazilian Real-Life Study about HCV treatment. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. Ann Hepatol 2019;18:849-54. [PMID: 31537509 DOI: 10.1016/j.aohep.2019.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
12 Mondschein S, Yankovic N, Matus O. Age‐dependent optimal policies for hepatitis C virus treatment. Intl Trans in Op Res 2021;28:3303-29. [DOI: 10.1111/itor.12705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Buonomo AR, Scotto R, Zappulo E, Nerilli M, Pinchera B, Perruolo G, Formisano P, Nappa S, Gentile I. Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. In Vivo 2019;33:177-82. [PMID: 30587620 DOI: 10.21873/invivo.11456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
14 Lanini S, Scognamiglio P, Pisapia R, Minosse C, Agresta A, Ippolito G. Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy. Int J Antimicrob Agents 2019;53:559-63. [PMID: 30550818 DOI: 10.1016/j.ijantimicag.2018.11.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Adland E, Jesuthasan G, Downs L, Wharton V, Wilde G, McNaughton AL, Collier J, Barnes E, Klenerman P, Andersson M, Jeffery K, Matthews PC. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort. BMC Infect Dis 2018;18:461. [PMID: 30217169 DOI: 10.1186/s12879-018-3367-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]